ANTITUMOR AGENT COMPOSED OF PROSTAGLANDIN D2, DEHYDRATED PROSTAGLANDIN D2 DERIVATIVE OR PROSTAGLANDIN A2

摘要

PURPOSE:To provide an antitumor agent containing a compound selected from prostaglandin D2, dehydrated prostaglandin D2 derivative and prostaglandin A2, as an active component. CONSTITUTION:A compound selected from the group of prostaglandin D2 (PGD2) of formulaI, dehydrated PGD2 derivative of formula II and prostaglandin A2 (PGA2) of formula III is used as an active component of an antitumor agent. Since PGD2 has weaker activity to contract the smooth muscle than the prostaglandin E compound, it can be administered in sufficiently high dose to exhibit the antitumor effect. The dehydrated PGD2 derivative and the PGA2 of formula III which is the dehydrated type of PGE2 have further stronger antitumor activity, and the existence of the 5-membered ring structure of formula IV or formula V is essential for the development of the strong antitumor activity. the DNA synthesis inhibiting action of the compound can be cited as one of the mechanisms of the cell proliferation suppressing activity of the compound.